ANTM

CVS Health Under Review – Hit by a Storm of Negativity

by

Image Source: Mike Mozart We are putting the fair value estimate of CVS Health under review while we re-evaluate the competitive environment and reassess the company’s appetite for leverage, which could impact dividend health. Brian Nelson, CFA Boy has CVS Health (CVS) been hit by a storm of negativity in recent months. After we added it to the newsletter portfolios, the company has gotten caught up in a whirlwind of investor concern regarding Amazon’s (AMZN) probable entrance in the pharmacy market. We noted as much in our September 30 note, “Amazon Casts a Large Shadow Over the Pharmacy Market,” and we said that even we were “growing more and more cautious on shares,” as we pointed to Amazon’s potential acquisition … Read more

Dividend Increases/Decreases for the Week Ending September 8

by

Below we provide a list of firms that raised/lowered their dividends during the week ending September 8. The dividend reports of covered firms on this list will be updated shortly with the new information. To access our dividend reports use the ‘Symbol’ search box in our website header. Firms Raising Their Dividends This Week Anthem (ANTM): now $0.70 per share quarterly dividend, was $0.65. BHP Billiton (BHP): now $0.86 per ADS semi-annual dividend, was $0.80. BIOQUAL (BIOQ): now $0.60 per share annual dividend, was $0.45. Blue Hills Bancorp (BHBK): now $0.15 per share quarterly dividend, was $0.05. Brady (BRC): now $0.2075 per share quarterly dividend, was $0.205. Brinker (EAT): now $0.38 per share quarterly dividend, was $0.34. Clough Global Allocation … Read more

Can Vertex Pharmaceuticals Dominate the Race to Treat Cystic Fibrosis?

by

Tickerized for holdings in the XLV and IBB. Cystic Fibrosis is a rare disease that afflicts an estimated seventy-five thousand patients worldwide. Vertex Pharmaceuticals is the first to market with a combination treatment to treat a portion of the overall patient population. Will Vertex win the race to bring forth a triple therapy to treat the vast majority of those afflicted? By Alexander J. Poulos Cystic fibrosis (CF) is a recessive genetic disorder. The patient that is afflicted will carry two copies of the cystic fibrosis conductance regulator protein (CFTR) gene. The CFTR gene allows the body to produce the CFTR protein, whose function is to remove chloride from the cells. Patients that have CF will suffer from a “thickening” … Read more

PBMs: Express Scripts and CVS’ Looming Victory?

by

Image Source: Victor We’re expecting a big win at CVS in coming years, and it may come at the expense of Express Scripts. By Alexander J. Poulos With the recent addition of CVS Health (CVS) to the newsletter portfolios, we believe the sell off in the Pharmaceutical Benefit Managers (PBM) industry is overdone. We are intrigued by the free cash flow generated from a highly-predictable business model, and that the PBM’s negotiate contracts in advance, locking in a customer for an extended period, only adds to the attractiveness of their operations. Another PBM, but a pure play, is Express Scripts (ESRX). Let’s discuss the unique characteristics of Express Scripts along with notable risks, which prevented us from adding the name … Read more

Pharma, Biotech and How to Consider Investing In It

by

The Valuentum analyst team digs deep into recent trends in big pharma and biotech from the lofty pricing of drugs to political and competitive pressures to ETF considerations and beyond. ~10 mins. If you cannot view the podcast below, please view the transcript below or select the link here. Tickerized for holdings in the XLV and IBB. Brian Nelson, CFA Gilead’s (GILD) hepatitis C regimen, almost a hundred thousand dollars. Vertex’s (VRTX) cystic fibrosis drug — hundreds of thousands of dollars per year. Have the drug companies lost their mind? This is Brian Nelson from Valuentum Securities, and today joining me is Mr. Kris Rosemann and Mr. Chris Araos — and we are going to talk everything healthcare, biotech… Mr. … Read more

Dividend Increases/Decreases for the Week Ending February 19

by

Below we provide a list of firms that raised/lowered their dividends during the week ending February 19. The dividend reports of covered firms on this list will be updated shortly with the new information. To access our dividend reports use the ‘Symbol’ search box in our website header. Firms Raising Their Dividends This Week Analog Devices (ADI): now $0.42 per share quarterly dividend, was $0.40. Anthem (ANTM): now $0.65 per share quarterly dividend, was $0.625. Argo Group (AGII): now $0.22 per share quarterly dividend, was $0.20. Autoliv (ALV): now $0.58 per share quarterly dividend, was $0.56. B/E Aerospace (BEAV): now $0.21 per share quarterly dividend, was $0.19. Coca-Cola (KO): now $0.35 per share quarterly dividend, was $0.33. Coca-Cola Enterprises (CCE): … Read more

Dividend Increases/Decreases for the Week Ending February 1

by

Below we provide a list of firms that raised their dividends during the week ending February 1. The dividend reports of covered firms on this list will be updated shortly with the new information. To access our dividend reports use the ‘Symbol’ search box in our website header. Firms Raising Their Dividends This Week AFLAC (AFL): now $0.27 per share quarterly dividend, was $0.26. ALLETE (ALE): now $0.5875 per share quarterly dividend, was $0.56. Alliance Resource Partners (ARLP): now $0.53 per share quarterly dividend, was $0.525. Anthem (ANTM): now $0.80 per share quarterly dividend, was $0.75. Arthur J. Gallagher (AJG): now $0.43 per share quarterly dividend, was $0.41. Bank of Botetourt (BORT): now $0.16 per share quarterly dividend, was $0.15. … Read more

WBA, ESRX, CVS: Earnings Update for the Pharmacy Services Industry

by

Image Source: Mike Mozart The first-quarter earnings performance across the pharmacy services industry has been a proverbial mixed bag with uncertainty continuing to weigh on performance. We continue to be interested in the industry for its defensive and strong free cash flow characteristics that bode well for dividend hikes and share repurchases going forward. We like CVS the most. By Alexander J. Poulos Walgreens Boots Alliance Remains Mired in Holding Pattern Shares of Walgreens Boots Alliance (WBA) reported a relatively in-line first quarter, its fiscal second quarter, on April 5, and all eyes continue to be focused on the pending Rite Aid (RAD) acquisition. We have been fans of the moves taken by Walgreens post the Alliance deal that saw … Read more

VIDEO/TRANSCRIPT: 2021 Valuentum Exclusive Call: Inflation Is Good

by

Valuentum’s President Brian Michael Nelson, CFA, explains why investors should not fear inflation, why government agencies such as the Fed and Treasury are prioritizing something other than price discovery, why the 10-year Treasury rate is a must-watch metric, and why Valuentum prefers the moaty constituents in large cap growth due to their net cash rich balance sheets, tremendous free cash flow generating potential, and secular growth tailwinds. Transcript: << Valuentum’s Best Ideas On behalf of the Valuentum team, I’d like to present to you our prepared remarks for the Valuentum Exclusive conference call for 2021. It is both an honor and a privilege to share our team’s work with you, and I personally am very grateful for your continued interest … Read more

8 Announcements and Top Research You May Have Missed

by

8 Announcements. This article was sent to members via email March 27. By Brian Nelson, CFA Hi everyone, Brian here. Trust you are doing great! Here are eight announcements I want you to be aware of: Everything we do is for our members. We’re very proud of the outperformance of the Best Ideas Newsletter portfolio, that we’ve never had a dividend cut in the Dividend Growth Newsletter portfolio, that our high-yield ideas are holding up very well, and the success rates of the Exclusive capital-appreciation ideas and short-idea considerations are running at approximately 80%. We’re proud to be your research partner. The odds of a Fed rate cut are going up as yield-curve inversion continues to threaten. The risks are more behavioral in … Read more